¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, ±â¼úº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030
»óǰÄÚµå : 1714900
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 371 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,991,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,393,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,511,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,125,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì(IRS) ½ÃÀå ±Ô¸ð´Â 2025³â 3¾ï 3,400¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 5¾ï 6,500¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£ Áß CAGRÀº 9.6%·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¸é¿ª ºÐ¼® ±â¹Ý ¿¬±¸ ¼Ö·ç¼ÇÀÇ È¿À²¼º, ¹Î°¨µµ, È®À强À» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, NGS ÅëÇÕ, ÀÚµ¿ ¾×ü ó¸® ½Ã½ºÅÛ, ÇÏÀ̽º·çDz ½ºÅ©¸®´× Ç÷§Æû°ú °°Àº ±â¼ú Çõ½ÅÀ¸·Î º¸´Ù ºü¸£°í Á¤È®ÇÑ ºÐ¼® °á°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. º¸´Ù ºü¸£°í Á¤È®ÇÑ ºÐ¼® °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí, ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ½Ç¼ö¸¦ ÁÙÀ̰í, 󸮷®À» Áõ°¡½ÃÄÑ IRSÀÇ ±â¼úÀ» ¿¬±¸ ¹× ÀÓ»ó Àû¿ë¿¡ ´õ¿í À¯¿ëÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÀÇ·á¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·áÁø°ú ¿¬±¸ÀÚµéÀº ƯÁ¤ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °¨ÁöÇϰí ȯÀÚ °³°³Àο¡ ¸Â´Â Ä¡·á¸¦ ÇÒ ¼ö ÀÖ´Â ÅøÀ» Á¡Á¡ ´õ ¸¹ÀÌ ÇÊ¿ä·Î Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó IRS ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç¥Àû Ä¡·á·ÎÀÇ ÀüȯÀº µ¿¹Ý Áø´Ü, Ä¡·á ¸ð´ÏÅ͸µ, ¸ÂÃã Ä¡·á Àü·«À» Áö¿øÇϵµ·Ï ¼³°èµÈ ƯÁ¤ ºÐ¼® ŰƮ ¹× ½Ã¾àÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ÀÓ»óÀû ÆÇ´ÜÀ» À§ÇÑ Á¤È®ÇÑ È¯ÀÚ Á᫐ µ¥ÀÌÅ͸¦ Á¦°øÇÏ°í °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â ¸é¿ª ºÐ¼® ±â¼ú¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó¿¬µµ 2024-2030³â
±âÁØ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2024-2030³â
°ËÅä ´ÜÀ§ ±Ý¾×(100¸¸ ´Þ·¯)
ºÎ¹® Á¦Ç°º°, ±â¼úº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

¿¹Ãø ±â°£ Áß ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì Á¦Ç° ½ÃÀå¿¡¼­ ±â¼úº° Á¡À¯À²Àº ½ÃÄö½Ì ±â¼ú ºÐ¾ß°¡ ÃÖ´ë¿´½À´Ï´Ù.

2024³â ½ÃÄö½Ì ±â¼úÀº ±â¼úº° IRS Á¦Ç° ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀåÀ» Â÷ÁöÇß½À´Ï´Ù. ½ÃÄö½Ì ±â¼úÀº ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ¿¬±¸ÀÇ ÇÙ½ÉÀ¸·Î, NGS ±â¼úÀÇ ¹ßÀüÀ¸·Î ¸®µå ±æÀÌ, 󸮷®, ¼Ò¿ä ½Ã°£ÀÌ °³¼±µÇ´Â ÇÑÆí, 1ȸ´ç ½ÇÇà ºñ¿ëÀÌ Å©°Ô °¨¼ÒÇϰí, ½ÃÄö½ÌÀÇ È®À强ÀÌ Çâ»óµÇ¾î ÀÓ»ó ¹× ¿¬±¸ ȯ°æ Àü¹Ý¿¡ °ÉÃÄ ÀÌ¿ëÀÌ ¿ëÀÌÇØÁ³½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ ²÷ÀÓ¾ø´Â Ç÷§Æû ±â¼ú Çõ½ÅÀ¸·Î ¸é¿ªÁ¾¾çÇÐ, °¨¿°¼º Áúȯ ÇÁ·ÎÆÄÀϸµ, ¹é½Å °³¹ß µî ´Ù¾çÇÑ ¿ëµµ¸¦ Áö¿øÇÏ´Â °íÈ¿À², »ç¿ëÇϱ⠽¬¿î ½ÃÄö¼­°¡ »ó¿ëÈ­µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀº Çмú ¹× »ó¾÷Àû ¿¬±¸ ȯ°æ ¸ðµÎ¿¡¼­ ³ôÀº äÅ÷ü°ú ÇÔ²² ½ÃÄö½Ì ±â¼úÀ» IRS Á¦Ç° ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀåÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ Áß ÃÖÁ¾»ç¿ëÀÚº° ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì Á¦Ç° ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÑ °ÍÀº Çмú¿¬±¸ ±â°üÀ̾ú½À´Ï´Ù.

Çмú¿¬±¸±â°üÀº ºÐ¼® ŰƮ, ½Ã¾à, ±â±â, ¼ÒÇÁÆ®¿þ¾î µî IRS Á¦Ç°ÀÇ °¡Àå Å« ÃÖÁ¾ »ç¿ëóÀÔ´Ï´Ù. ´ëÇÐ ¹× Çмú ÀÇ·á¼¾ÅÍ¿¡¼­´Â ¸é¿ª ÇÁ·ÎÆÄÀϸµ, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö, Áúº´ ±âÀü ±Ô¸í µî IRS ±â¼ú¿¡ Å©°Ô ÀÇÁ¸Çϴ Ž»öÀû ¿¬±¸ ¹× °¡¼³¿¡ ±â¹ÝÇÑ ¿¬±¸°¡ ¸¹ÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ºÐ¼® ŰƮ, ½Ã¾à, ½ÃÄö½Ì Àåºñ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ ¼ö¿ä´Â ´Ù¾çÇÑ ¿¬±¸ ÇÁ·Î±×·¥ÀÌ À¯¿¬Çϰí È®Àå °¡´ÉÇϸç Á¤¹ÐÇÑ ÅøÀ» ÇÊ¿ä·Î ÇÏ´Â Çмú±â°ü¿¡¼­ Ç×»ó ³ô½À´Ï´Ù. ¶ÇÇÑ ¸é¿ªÇÐ, Á¾¾çÇÐ, °¨¿°º´ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ¹× ¿¬±¸±â°üÀÇ ÀÚ±Ý Áö¿øÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ Çмú±â°ü¿¡¼­ IRS ±â¼úÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Á¶»ç ±â°£ Áß ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ IRS ½ÃÀåÀº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ¼ºÀåÀº ÇコÄɾî ÀÎÇÁ¶ó °³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ »ýÀÇÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. Áß±¹, Àεµ, Çѱ¹, ÀϺ» µî °¢±¹ Á¤ºÎ´Â IRS¸¦ Æ÷ÇÔÇÑ »ý¸í°úÇÐ ¹× Á¤¹ÐÀÇ·á ±¸»óÀ» Áö¿øÇϱâ À§ÇØ ¸¹Àº ÀÚ±ÝÀ» ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ Àα¸¿Í ³·Àº ¿î¿µ ºñ¿ëÀ¸·Î ÀÎÇÑ °Å´ëÇÑ ¼ºÀå ÀáÀç·ÂÀ» °í·ÁÇÑ ÁÖ¿ä Áö¿ª ±â¾÷ÀÇ ÅõÀÚ Áõ°¡µµ ¿¹Ãø ±â°£ Áß ÀÌ Áö¿ªÀÇ ±Þ°ÝÇÑ ¼ºÀåÀ» Áö¿øÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù.

¼¼°èÀÇ ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Á¦Ç°º°, ±â¼úº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ÀÇ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå(Á¦Ç°º°)

Á¦7Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì Á¦Ç° ½ÃÀå(±â¼úº°)

Á¦8Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ¼­ºñ½º ½ÃÀå(¿öÅ©Ç÷ο캰)

Á¦9Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå(¿ëµµº°)

Á¦10Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì Á¦Ç° ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦11Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ¼­ºñ½º ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦12Àå ¸é¿ª ·¹ÆÛÅ丮 ½ÃÄö½Ì ½ÃÀå(Áö¿ªº°)

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period. This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD million)
SegmentsProduct (Technology, End User), Service (Workflow, End User), Application
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period.

In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time-making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market.

Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period.

Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings.

The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period.

The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region's fastest growth during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

List of Companies Profiled in the Report:

Research Coverage:

This report provides a detailed picture of the global IRS market. It aims to estimate the market's size and future growth potential across different segments such as the product, service, application product-technology, product-end user, service-end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem.

Reasons to Buy this Report :

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT

7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY

8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW

9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION

10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER

11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER

12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES

15 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â